With a market cap of $931.3 billion, Eli Lilly and Company (LLY) discovers, develops, manufactures, and markets medicines across major regions including the United States, Europe, China, and Japan. Its portfolio spans treatments for diabetes, cancer, immunological conditions, neurological disorders, and obesity, supported by strategic collaborations with companies like Boehringer Ingelheim and F. Hoffmann-La Roche.
Shares of the pharmaceutical giant have slightly lagged behind the broader market over the past 52 weeks. LLY stock has increased 28.2% over this time frame, while the broader S&P 500 Index ($SPX) has gained 30.6%. In addition, the stock has declined 7.5% on a YTD basis, compared to SPX's 7% gain.
Looking closer, shares of the Indianapolis, Indiana-based company have outpaced the State Street Health Care Select Sector SPDR ETF's (XLV) 8.8% rise over the past 52 weeks.
Shares of Eli Lilly jumped 9.8% on Apr. 30 after it raised its 2026 guidance to $82 billion - $85 billion in revenue and adjusted EPS of $35.50 - $37. The surge was also driven by Q1 2026 revenue growth of 56% year-over-year, fueled by blockbuster demand for Mounjaro and Zepbound, which together generated $12.8 billion in sales. Additionally, investor optimism increased following the FDA approval and launch of Foundayo (orforglipron), with early uptake (over 20,000 patients and 8,000 prescribers) reinforcing confidence in Lilly’s next growth driver.
For the fiscal year ending in December 2026, analysts expect LLY’s adjusted EPS to jump nearly 47% year-over-year to $35.58. The company's earnings surprise history is promising. It beat the consensus estimates in the last four quarters.
Among the 30 analysts covering the stock, the consensus rating is a “Strong Buy.” That’s based on 23 “Strong Buy” ratings, three “Moderate Buys,” and four “Holds.”
On May 5, Barclays analyst Emily Field raised the price target for Eli Lilly to $1,400, maintaining an “Overweight” rating.
The mean price target of $1,230.75 represents a 23.9% premium to LLY’s current price levels. The Street-high price target of $1,500 suggests a 51% potential upside.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
- With Earnings Ahead, Wait for a Dip Before You Buy CoreWeave Stock
- Sandisk Stock Is up Nearly 500% in 2026. Q3 Results Show Its Data Center Business Is Still Growing.
- The Biggest Catalyst for OKLO Stock May Not Be Earnings, But a Brewing Short Squeeze
- 7 Stocks Worth Buying the Dip in Now... Or At Least Adding to Your Watchlist